Featured stories
This section of our website is the best initial point of contact for journalists with inquiries about GlycoSyn. Our most recent media releases are on this page.
-
Dec 2011Glycosylation of the MUC1-peptide antigen component of a fully synthetic tripartite cancer vaccine proved to be a critical requirement for triggering an effective response involving both humoral and cellular immune responses.
-
Apr 2010Industrial Research Ltd (IRL) and Epichem Pty Ltd today announced the launch of a strategic alliance designed to provide clients with continuous and seamless services from drug discovery to cGMP production.
-
Jan 2010A promising new gout treatment co-discovered by Lower Hutt’s Industrial Research Ltd (IRL) has taken an important step towards the world’s largest pharmaceuticals market.
-
Oct 2008A vaccine for cancer is being developed by a new collaboration between Victoria Link, the Malaghan Institute, IRL and Grow Wellington.
-
Dec 2006IRL’s Distinguished Scientist, Dr Richard Furneaux, has been awarded the Hector Medal from the Royal Society of New Zealand.
-
Aug 2006GlycoSyn has nearly completed the manufacture of the key ingredient for a new drug designed to slow the progression of Parkinson’s Disease.
-
Jul 2006The active ingredient for a new drug designed to prevent genital herpes and HIV-AIDS will be manufactured in New Zealand with the signing of a major contract.
-
Mar 2005Starpharma Holdings Limited (ASX: SPL, USOTC:SPHRY) of Melbourne, Australia and Industrial Research Limited, New Zealand, today announced that they have entered into a joint venture to accelerate the development of carbohydrate functionalised dendrimers (glycodendrimers) for use in therapeutics, antigen presentation and as biologically active compounds.